优化前列腺癌根治性前列腺切除术后挽救性放疗的时机及同期激素治疗的使用
本文综述2000年1月1日至2018年1月10日文献,共33篇独立报告(含2项评估同期激素治疗的随机试验)。回顾性数据提示较低的挽救性放疗前PSA水平与更好临床结局相关;前瞻性数据提示同期激素治疗有总生存获益,但假设生成性亚组分析提示获益可能仅限于挽救性放疗前PSA较高者。结论强调医患共同决策及进一步研究。
要点
- 回顾性数据支持在较低的挽救性放疗前PSA水平启动挽救性放疗,无任意绝对阈值。
- 前瞻性数据提示同期激素治疗有总生存获益,但可能仅限于挽救性放疗前PSA较高者。
- 不良风险因素如Gleason分级分组4-5者可能从更早挽救性放疗和/或激素治疗中获益最大。
核心结论
- 鉴于现有数据的局限性,医生必须参与共同决策,推荐应个体化权衡最大化肿瘤获益(有过度治疗风险)与优化生活质量(有治疗不足风险)。
- 大量回顾性数据支持在较低的挽救性放疗前PSA值启动挽救性放疗,无任意绝对阈值。
- 前瞻性数据提示激素治疗获益,但该获益可能在挽救性放疗前PSA高于大多数接受「早期」挽救性放疗患者典型水平的患者中最大。
- 在作出绝对推荐前需进一步研究。
研究设计与样本
- 检索MEDLINE(通过PubMed)、EMBASE、Cochrane对照试验中心注册库及专业组织指南声明,时间范围为2000年1月1日至2018年1月10日。
- 共识别33篇独立报告,包括2项评估挽救性放疗联合激素治疗的随机试验。
主要发现
- 回顾性数据提示,在较低的挽救性放疗前PSA水平启动挽救性放疗与更好的临床结局相关。
- 前瞻性数据提示同期激素治疗有总生存获益,该获益在长期随访中显现;但假设生成性亚组分析提示该获益可能仅限于挽救性放疗前PSA较高的患者。
- 具有不良风险因素(如Gleason分级分组4-5)的患者可能从更早启动挽救性放疗和/或使用激素治疗中获益最大。
临床怎么用
- 医生应参与共同决策,推荐应个体化权衡最大化肿瘤获益(有过度治疗风险)与优化生活质量(有治疗不足风险)。
- 在共同决策框架内,大量回顾性数据支持在较低的挽救性放疗前PSA值启动挽救性放疗,无任意绝对阈值。
- 前瞻性数据提示激素治疗获益,但该获益可能在挽救性放疗前PSA高于大多数接受「早期」挽救性放疗患者典型水平的患者中最大。
- 在作出绝对推荐前需进一步研究。
局限性
- 现有数据存在局限性。
- 假设生成性亚组分析提示激素治疗获益可能仅限于挽救性放疗前PSA较高的患者。
- 在作出绝对推荐前需进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Currently, salvage radiotherapy (SRT) is the only known curative intervention for men with recurrent disease following prostatectomy. Critical issues in the optimal selection and management of men being considered for SRT include the threshold prostate-specific antigen (PSA) value at which to initiate treatment (ie, pre-SRT PSA) and the role of concurrent hormonal therapy (HT). OBJECTIVE: To review the published evidence pertaining to the optimal timing for SRT and the role of concurrent HT. EVIDENCE ACQUISITION: MEDLINE (via PubMed), EMBASE, the Cochrane Central Register of Controlled Trials, and guideline statements from professional organizations were queried from January 1, 2000 through January 10, 2018. EVIDENCE SYNTHESIS: Thirty-three independent reports, including two randomized trials evaluating HT with SRT, were identified. Retrospective data suggest that SRT initiation at lower pre-SRT PSA levels is associated with better clinical outcomes. Prospective data suggest an overall survival benefit with concurrent HT that manifests during long-term follow-up, with the caveat that hypothesis-generating subgroup analyses suggest that this benefit may be limited to patients with higher pre-SRT PSA levels. Patients with adverse risk factors, such as Gleason grade group 4-5 disease, are likely to benefit the most from earlier SRT initiation and/or the use of HT. CONCLUSIONS: Given the limitations of the available data, it is imperative that physicians participate in shared decision-making, with the recommendation tailored for each man's desire to maximize oncologic benefit (with a risk of overtreatment) versus potential quality-of-life optimization (with a risk of undertreatment). Within that framework, a significant body of retrospective data supports initiation of SRT at low pre-SRT PSA values, without an arbitrary absolute threshold. Prospective data suggest a benefit of HT, but this benefit may be greatest in patients with a pre-SRT PSA that is higher than the typical level in most patients receiving "early" SRT. Further research is necessary before absolute recommendations can be made. PATIENT SUMMARY: Two ways to potentially improve outcomes following salvage radiotherapy for prostate cancer that recurs after prostatectomy are to start treatment at a lower prostate-specific antigen level and to use concurrent hormonal therapy. Our review suggests that the available evidence is imperfect, but highlights that both measures are likely to improve clinical outcomes in general, but perhaps not uniformly and/or consistently for all patients. Physician-patient shared decision-making and further research are critical.
引用
- Kishan AU, Tendulkar RD, Tran PT, et al. Optimizing the Timing of Salvage Postprostatectomy Radiotherapy and the Use of Concurrent Hormonal Therapy for Prostate Cancer. Eur Urol Oncol. 2018. PMID: 31100226. doi:10.1016/j.euo.2018.02.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。